Acutus Medical (Acutus Medical) ROCE % : 285.85% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Acutus Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acutus Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was 285.85%.

Acutus Medical ROCE % Historical Data

The historical data trend for Acutus Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acutus Medical ROCE % Chart

Acutus Medical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-200.38

-79.00

-69.59

25.67

-8.35

Acutus Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															323.67	-56.51	-74.94	-61.84	285.85

Acutus Medical ROCE % Calculation

Acutus Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-6.203	/	( ( (133.44 - 19.872)	+	(53.96 - 18.942) )	/ 2 )
	=	-6.203	/	( (113.568	+	35.018)	/ 2 )
	=	-6.203	/	74.293
	=	-8.35 %

Acutus Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	150.04	/	( ( (84.728 - 14.767)	+	(53.96 - 18.942) )	/ 2 )
	=	150.04	/	( ( 69.961	+	35.018 )	/ 2 )
	=	150.04	/	52.4895
	=	285.85 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Acutus Medical (OTCPK:AFIB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acutus Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Acutus Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acutus Medical (Acutus Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acutus Medical Inc (OTCPK:AFIB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008

Website

https://www.acutusmedical.com

Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.

Executives

Takeo Mukai	officer: Interim CFO	C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Jason K Garland	director	10000 WEHRLE DRIVE, CLARENCE NY 14031
Kevin Mathews	officer: SVP, Global Sales	C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Charlie Piscitello	officer: Chief People Officer	2210 FARADAY AVE #100, CARLSBAD CA 92008
Tom Sohn	officer: SVP, Gen. Counsel & Secretary	2210 FARADAY AVE #100, CARLSBAD CA 92008
R Scott Huennekens	director	C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
James F. Hinrichs	director	3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Niamh Louise Pellegrini	director	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James E Flynn	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Orbimed Capital Gp Iv Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
John F Sheridan	director	C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
David Roman	officer: SVP & Chief Financial Officer	ACUTUS MEDICAL, INC., 2210 FARADAY AVE, SUITE 100, CARLSBAD CA 92008